On April 12, 2023 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, reported the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time (Press release, Chemomab, APR 12, 2023, View Source [SID1234629988]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This webcast and call replaces and supplements a previously announced Corporate Update event that had been scheduled for April 17, 2023.
During the event, Chemomab’s management team will review first quarter 2023 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the webcast and call will be available on Chemomab’s website for 90 days at www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Thursday, May 11, 2023
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID code: 13735393
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.
Or click on Call meTM starting 15 minutes before the scheduled start time for instant telephone access without having to wait for an operator.